Phase 3 Study of Selpercatinib Meets Primary PFS End Point i

Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.

Related Keywords

Eli Lilly , David Hyman , Selpercatinib Retevmo , Lung Cancer , Non Small Cell Lung Cancer , Nsclc , Selpercatinib , Ret Fusion Positive Advanced , Metastatic , Libretto 431 ,